This distinct phenotype plasticity of tumor cells in response to BRAF/MEK inhibition is partly regulated epigenetically—an in-depth review of the epigenetic mechanisms underlying the drug resistance is available elsewhere [111]. The gene discussed is MAP2K7; the disease is neoplasm.